Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

(2018) Diansong Zhou et al.   CLINICAL PHARMACOKINETICS

Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet formulations in Oncology Patients

(2018) Diansong Zhou et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Considering renal risk while managing cancer

(2017) Vahakn B Shahinian et al.   Cancer Management and Research

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

(2016) J. Mateo et al.   Targeted Oncology

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

(2015) Camille C Gunderson et al.   Future Oncology

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

(2010) J.E. Ang et al.   EJC SUPPLEMENTS